Furthermore, no significant weight loss was observed in the mice during treatment period, suggesting that cetuximab, ramucirumab or anti-EGFR/VEGFR2 BsAb treatment did not cause any systemic toxicity in tumor-bearing mice (Figure 4D). Here, EGFR is linked to neoplasm.